KN046, a bispecific antibody targeting PD-L1 and CTLA4, also showed promising results in combination with systemic chemotherapy, with an ORR of 46% (95% CI, 35.2–57.0%) and a median DOR of 8.1 (95% CI, 4.14–13.90) months in a phase II study of advanced metastatic NSCLC [96]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.